Dr. Vogel, I'm so glad you're here. I've been wanting to have somebody come and talk about the Swiss model for a long time.
I think what we're observing in this room today is a microcosm of the debate about safe supply, where we have the Hedicans passionately advocating for safe supply because it's a toxic drug supply that's killing people, and on the other hand, we have Chief Truong talking about diversion and the concern that diversion creates this very cheap supply of narcotics that may be the entry-level narcotics.
I've certainly heard this, for example, from B.C. psychiatrists who deal with the population on the streets. I asked them why kids start on Dilaudid, and they said, “Well, they're cheap.” The price went from $20 at one time, and after safe supply came in, it was one dollar, whereas a joint is five dollars on the street. What are you going to get, the joint or the Dilaudid?
You start on Dilaudid. No, Dilaudid doesn't kill you, but the problem with narcotics is you get used to them and you have to go to something stronger. That's what's happening, and the concern is people are selling the Dilaudid and then using fentanyl, and it's the fentanyl that kills people.
What's the answer to balance these? I think, in large part, it's what the Swiss do.
Dr. Vogel, do you agree that the whole basis of the Swiss model is observed treatment? For the vast majority of people who are on stronger drugs like heroin, they're not going to be okay with oral pills anyhow, so you give them an injectable, but they have to come in and take it there. The vast majority of the HAT program is observed treatment. Is that correct?